Stay updated on Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page.

Latest updates to the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe completed KEYNOTE-033 Phase 3 study record is now available, detailing pembrolizumab versus docetaxel for previously treated non-small cell lung cancer, along with its eligibility criteria, measures, investigators, publication, and study documents.SummaryDifference57%

- Check16 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA sitewide NIH notice announces that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during a transition. The clinical trial page itself continues to display a 403 error.SummaryDifference1%

- Check30 days agoChange DetectedThe site revision label in the footer changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1; the page still displays a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study page now renders a 403 Forbidden error, signaling that the page is temporarily inaccessible. The usual study details and navigation are replaced by the error screen.SummaryDifference19%

Stay in the know with updates to Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page.